Novel Bio is a lean, technology-differentiated CDMO providing a secure, domestic alternative for your critical raw materials. By combining optimized traditional E. coli platforms with agile operations, we deliver R&D, High-Quality (HQ), and GMP-grade plasmid DNA to help you meet your clinical milestones with fiscal and regulatory certainty at 50% or more the costs of other providers. We aim to overcome the DNA bottleneck and help bring a new generation of medicine to patients.